Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-09T14:56:13.186Z Has data issue: false hasContentIssue false

20 - Metabolic complications of antiretroviral therapy in children

from Part III - Antiretroviral therapy

Published online by Cambridge University Press:  03 February 2010

By
Carol J. Worrell
Edited by
Steven L. Zeichner  and
Jennifer S. Read
Carol J. Worrell
Affiliation:
HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892
Steven L. Zeichner
Affiliation:
National Cancer Institute, Bethesda, Maryland
Jennifer S. Read
Affiliation:
National Cancer Institute, Bethesda, Maryland
Get access

Summary

Introduction

The introduction of highly active antiretroviral therapy (HAART) has revolutionized the care of HIV-1 infected children and adults in the developed world. As the morbidity and mortality attributable to the complications of HIV infection itself have decreased, the recognition of unforeseen toxicities attributable to HAART has increased. Pediatricians who care for HIV-infected children and adolescents increasingly face a population that has had extensive and prolonged exposure to HAART. There is mounting evidence in the adult literature that the magnitude and breadth of toxicities associated with HAART can be substantial, yet there remains considerable uncertainty with respect to the definitions of particular syndromes, their etiology, their prevalence, the appropriate diagnostic criteria to be used in identifying them, and their management. Further, the consequences of these changes for the overall health of the patients remain unclear. The pediatric data are quite limited, and the available information suggests that the manifestations of such toxicities in HIV-infected children can be subtle and may vary with developmental stage, with different patterns manifesting in younger children than have been described in adults. Metabolic complications have been reported in association with the use of nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs). Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have not been directly implicated. There may be significant intra-class variability, with individual drugs within a given class associated more strongly than others with specific complications.

Type
Chapter
Information
Textbook of Pediatric HIV Care , pp. 319 - 333
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

John, M., Nolan, D. & Mallal, S.Antiretroviral therapy and the lipodystrophy syndrome. Antivir. Ther. 6: 1 (2001), 9–20Google ScholarPubMed
Mallal, S. A., John, M., Moore, C. B., James, I. R. & McKinnon, E. J.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with Human Immunodeficiency Virus infection. Acquired Immune Deficiency Syndrome 14: 10 (2000), 1309–16Google Scholar
Chene, G., Angelini, E., Cotte, L., et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 34: 5 (2002), 649–57CrossRefGoogle ScholarPubMed
Gervasoni, C., Ridolfo, A. L., Trifiro, G.. Redistribution of body fat in Human Immunodeficiency Virus-infected women undergoing combined antiretroviral therapy. Acquired Immune Deficiency Syndrome 13: 4 (1999), 465–71Google Scholar
Hadigan, C., Miller, K., Corcoran, C., Anderson, E., Basgoz, N. & Grinspoon, S.Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J. Clin. Endocrinol. Metab. 84: 6 (1999), 1932–7Google ScholarPubMed
Mynarcik, D. C., McNurlan, M. A., Steigbigel, R. T., Fuhrer, J. & Gelato, M. C.Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in Human Immunodeficiency Virus lipodystrophy. J. Acquired Immune Deficiency Syndrome 25: 4 (2000), 312–21CrossRefGoogle Scholar
Ledru, E., Christeff, N., Patey, O., Truchis, P., Melchior, J. C. & Gougeon, M. L.Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95: 10 (2000), 3191–8Google ScholarPubMed
Duong, M., Petit, J. M., Piroth, L.. Association between insulin resistance and hepatitis C virus chronic infection in Human Immunodeficiency Virus-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J. Acquired Immune Deficiency Syndrome 27: 3 (2001), 245–50CrossRefGoogle Scholar
Kotler, D. P., Rosenbaum, K., Wang, J. & Pierson, R. N.Studies of body composition and fat distribution in Human Immunodeficiency Virus-infected and control subjects. J. Acquired Immune Deficiency Syndrome Hum. Retrovirol. 20: 3 (1999), 228–37CrossRefGoogle Scholar
Grunfeld, C., Pang, M., Doerrler, W., Shigenaga, J. K., Jensen, P. & Feingold, K. R.Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74: 5 (1992), 1045–52Google ScholarPubMed
Lo, J. C., Mulligan, K., Tai, V. W., Algren, H. & Schambelan, M.“Buffalo hump” in men with Human Immunodeficiency Virus-1 infection. Lancet 351: 9106 (1998), 867–70CrossRefGoogle Scholar
Carr, A., Miller, J., Law, M. & Cooper, D. A.A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with Human Immunodeficiency Virus nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. Acquired Immune Deficiency Syndrome 14: 3 (2000), F25–32Google ScholarPubMed
Saint-Marc, T., Partisani, M., Poizot-Martin, I.. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. Acquired Immune Deficiency Syndrome 13: 13 (1999), 1659–67Google ScholarPubMed
Saint-Marc, T., Partisani, M., Poizot-Martin, I., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. Acquired Immune Deficiency Syndrome 14: 1 (2000), 37–49Google ScholarPubMed
Galli, M., Ridolfo, A. L., Adorni, F.. Body habitus changes and metabolic alterations in protease inhibitor-naive Human Immunodeficiency Virus-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquired Immune Deficiency Syndrome 29: 1 (2002), 21–31CrossRefGoogle Scholar
Mulligan, K., Tai, V. W., Algren, H., et al. Altered fat distribution in Human Immunodeficiency Virus-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J. Acquired Immune Deficiency Syndrome 26: 5 (2001), 443–8CrossRefGoogle Scholar
Mallon, P. W., Cooper, D. A. & Carr, A.Human Immunodeficiency Virus-associated lipodystrophy. Human Immunodeficiency Virus Med 2: 3 (2001), 166–73Google Scholar
Valk, M., Gisolf, E. H., Reiss, P.. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of Human Immunodeficiency Virus-1 infection. Acquired Immune Deficiency Syndrome 15: 7 (2001), 847–55Google Scholar
Hadigan, C., Corcoran, C., Stanley, T., Piecuch, S., Klibanski, A. & Grinspoon, S.Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J. Clin. Endocrinol. Metab. 85: 1 (2000), 35–41Google ScholarPubMed
Jain, R. G., Furfine, E. S., Pedneault, L., White, A. J. & Lenhard, J. M.Metabolic complications associated with antiretroviral therapy. Antiviral. Res. 51: 3 (2001), 151–77CrossRefGoogle ScholarPubMed
Carr, A., Samaras, K., Burton, S.. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving Human Immunodeficiency Virus protease inhibitors. Acquired Immune Deficiency Syndrome 12: 7 (1998), F51–8Google Scholar
Tsiodras, S., Mantzoros, C., Hammer, S. & Samore, M.Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160: 13 (2000), 2050–6CrossRefGoogle ScholarPubMed
Heath, K. V., Hogg, R. S., Chan, K. J.. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome treatment database. Acquired Immune Deficiency Syndrome 15: 2 (2001), 231–9Google Scholar
Struble, K. & Piscitelli, S. C.Syndromes of abnormal fat redistribution and metabolic complications in Human Immunodeficiency Virus-infected patients. Am. J. Health Syst. Pharm. 56: 22 (1999), 2343–8Google Scholar
Dong, K. L., Bausserman, L. L., Flynn, M. M.. Changes in body habitus and serum lipid abnormalities in Human Immunodeficiency Virus-positive women on highly active antiretroviral therapy (Highly Active Antiretroviral Therapy). J. Acquired Immune Deficiency Syndrome 21: 2 (1999), 107–13Google Scholar
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J. & Cooper, D. A.Diagnosis, prediction, and natural course of Human Immunodeficiency Virus-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 9170 (1999), 2093–9CrossRefGoogle ScholarPubMed
Herman, J. & Easterbrook, P.The metabolic toxicities of antiretroviral therapy. Int. J. STD Acquired Immune Deficiency Syndrome 12 (2001), 555–64Google ScholarPubMed
Qaqish, R., Rublein, J. & Wohl, D.Human Immunodeficiency Virus-associated lipodystrophy syndrome. Pharmacotherapy 20: 1 (2000), 13–22CrossRefGoogle Scholar
Wanke, C. A., Falutz, J. M., Shevitz, A., Phair, J. P. & Kotler, D. P.Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin. Infect. Dis. 34: 2 (2002), 248–59CrossRefGoogle ScholarPubMed
Saint-Marc, T. & Touraine, J. L.“Buffalo hump” in Human Immunodeficiency Virus-1 infection. Lancet 352: 9124 (1998), 319–20CrossRefGoogle Scholar
Shikuma, C. M., Waslien, C., McKeague, J.. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with Acquired Immune Deficiency Syndrome. Acquired Immune Deficiency Syndrome 13: 11 (1999), 1359–65Google Scholar
Carr, A. & Cooper, D. A.Adverse effects of antiretroviral therapy. Lancet 356: 9239 (2000), 1423–30CrossRefGoogle ScholarPubMed
Estrada, V., Serrano-Rios, M., Martinez, Larrad M. T.. Leptin and adipose tissue maldistribution in Human Immunodeficiency Virus-infected male patients with predominant fat loss treated with antiretroviral therapy. J. Acquired Immune Deficiency Syndrome 29: 1 (2002), 32–40CrossRefGoogle Scholar
Herry, I., Bernard, L., Truchis, P. & Perronne, C.Hypertrophy of the breasts in a patient treated with indinavir. Clin. Infect. Dis. 25: 4 (1997), 937–8CrossRefGoogle Scholar
Jaquet, D., Levine, M., Ortega-Rodriguez, E.. Clinical and metabolic presentation of the lipodystrophic syndrome in Human Immunodeficiency Virus-infected children. Acquired Immune Deficiency Syndrome 14: 14 (2000), 2123–8Google Scholar
Hadigan, C., Corcoran, C., Piecuch, S., Rodriguez, W. & Grinspoon, S.Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. J. Clin. Endocrinol. Metab. 85: 10 (2000), 3544–50Google ScholarPubMed
Christeff, N., Melchior, J. C., Mammes, O., Gherbi, N., Dalle, M. T. & Nunez, E. A.Correlation between increased cortisol:DHEA ratio and malnutrition in Human Immunodeficiency Virus-positive men. Nutrition 15: 7–8 (1999), 534–9CrossRefGoogle Scholar
Amaya, R., Kozinetz, C., McMeans, A., Schwarzwald, H. & Kline, M.Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 21: 5 (2002), 405–10CrossRefGoogle ScholarPubMed
Arpadi, S. M., Cuff, P. A., Horlick, M., Wang, J. & Kotler, D. P.Lipodystrophy in Human Immunodeficiency Virus-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J. Acquired Immune Deficiency Syndrome 27: 1 (2001), 30–4CrossRefGoogle Scholar
Meneilly, G., Forbes, J., Peabody, D., Remple, V. & Burdge, D. Metabolic and body composition changes in Human Immunodeficiency Virus-infected children on antiretroviral therapy. In 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Interleukin (2001)
Brambilla, P., Bricalli, D., Sala, N.. Highly active antiretroviral-treated Human Immunodeficiency Virus-infected children show fat distribution changes even in absence of lipodystrophy. Acquired Immune Deficiency Syndrome 15: 18 (2001), 2415–22Google Scholar
Savage, D. B. & O'Rahilly, S.Leptin: a novel therapeutic role in lipodystrophy. J. Clin. Invest. 109 (2002), 1285–6CrossRefGoogle ScholarPubMed
Flier, J. Obesity. In E. Braunwald, et al., (eds.), Harrison's Principles of Internal Medicine, 15th edn. New York McGraw-Hill Companies (2001)
Montague, C. T. & O'Rahilly, S.The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 6 (2000), 883–8CrossRefGoogle ScholarPubMed
Carr, A.Human Immunodeficiency Virus protease inhibitor-related lipodystrophy syndrome. Clin. Infect. Dis. 30 (Suppl. 2) (2000), S135–42CrossRefGoogle ScholarPubMed
Behrens, G., Dejam, A., Schmidt, H.. Impaired glucose tolerance, beta cell function and lipid metabolism in Human Immunodeficiency Virus patients under treatment with protease inhibitors. Acquired Immune Deficiency Syndrome 13: 10 (1999), F63–70Google ScholarPubMed
Powderly, W. G.Long-term exposure to lifelong therapies. J. Acquired Immune Deficiency Syndrome 29 (Suppl. 1) (2002), S28–40CrossRefGoogle ScholarPubMed
Mulligan, K., Grunfeld, C., Tai, V. W.. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with Human Immunodeficiency Virus infection. J. Acquired Immune Deficiency Syndrome 23: 1 (2000), 35–43CrossRefGoogle Scholar
Melvin, A. J., Lennon, S., Mohan, K. M. & Purnell, J. Q.Metabolic abnormalities in Human Immunodeficiency Virus type 1-infected children treated and not treated with protease inhibitors. Acquired Immune Deficiency Syndrome Res. Hum. Retrovir. 17: 12 (2001), 1117–23Google Scholar
Cheseaux, J. J., Jotterand, V., Aebi, C.. Hyperlipidemia in Human Immunodeficiency Virus-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J. Acquired Immune Deficiency Syndrome 30: 3 (2002), 288–93CrossRefGoogle Scholar
Bitnun, A., Sochett, E., Babyn, P. et al. Glucose homeostasis, serum lipids and abdominal adipose tissue distribution in protease inhibitor-treated and protease inhibitor-naive Human Immunodeficiency Virus-infected children. In 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA (2002)
Arpadi, S. M., Cuff, P. A., Horlick, M. & Kotler, D. P.Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired Human Immunodeficiency Virus infection receiving protease inhibitor-containing antiviral treatment. Acquired Immune Deficiency Syndrome 13: 16 (1999), 2312–3Google Scholar
Purnell, J. Q., Zambon, A., Knopp, R. H.. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. Acquired Immune Deficiency Syndrome 4: 1 (2000), 51–7Google Scholar
Carr, A., Samaras, K., Chisholm, D. J. & Cooper, D. A.Pathogenesis of Human Immunodeficiency Virus-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 9119 (1998), 1881–3CrossRefGoogle Scholar
Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I. & Falloon, J.Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 9106 (1998), 871–5CrossRefGoogle ScholarPubMed
Fetter, A., Nacci, P., Lenhard, J. et al. Fat distribution and retinoid-like symptoms are infrequent in NRTI-experienced subjects treated with amprenavir. In 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA (2000)
Joly, V., Flandre, P., Meiffredy, V. et al. Assessment of lipodystrophy in patients previously exposed to Zidovudine (also known as Zidovudine (also Known as AZT)), Didanosine, or Zalcitabine, but naive for Stavudine and protease inhibitors (Pentamidine Isothionate), and randomized between Stavudine/Lamivudine/Indinavir and AZT/Lamivudine/Indinavir (NOVAVIR trial). In 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001. Chicago, Interleukin (2001)
Brinkman, K., Smeitink, J. A., Romijn, J. A. & Reiss, P.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet354: 9184 (1999), 1112–5Google Scholar
Brinkman, K., Hofstede, H. J., Burger, D. M., Smeitink, J. A. & Koopmans, P. P.Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. Acquired Immune Deficiency Syndrome 12: 14 (1998), 1735–44Google ScholarPubMed
Cote, H. C., Brumme, Z. L., Craib, K. J.. Changes in mitochondrial Deoxyribonucleic Acid as a marker of nucleoside toxicity in Human Immunodeficiency Virus-infected patients. New Engl. J. Med. 346: 11 (2002), 811–20CrossRefGoogle Scholar
Kakuda, T. N.Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22: 6 (2000), 685–708CrossRefGoogle ScholarPubMed
Dube, M. P., Sprecher, D., Henry, W. K.. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy. Recommendations of the Adult Acquired Immune Deficiency Syndrome Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31: 5 (2000), 1216–24Google ScholarPubMed
The Adult Acquired Immune Deficiency Syndrome Clinical Trials Group. AACTG Metabolic Complications Guides. In Adult Acquired Immune Deficiency Syndrome Clinical Trials Group (2002)
American Academy of Pediatrics. Committee on Nutrition. “Cholesterol in childhood”. Pediatrics 101: 1 (1998), 141–7CrossRef
Wedekind, C. A. & Pugatch, D.Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 21: 7 (2001), 861–6CrossRefGoogle ScholarPubMed
Roubenoff, R., Weiss, L., McDermott, A.. A pilot study of exercise training to reduce trunk fat in adults with Human Immunodeficiency Virus-associated fat redistribution. Acquired Immune Deficiency Syndrome 13: 11 (1999), 1373–5Google Scholar
Jones, S. P., Doran, D. A., Leatt, P. B., Maher, B. & Pirmohamed, M.Short-term exercise training improves body composition and hyperlipidaemia in Human Immunodeficiency Virus-positive individuals with lipodystrophy. Acquired Immune Deficiency Syndrome 15: 15 (2001), 2049–51Google Scholar
Moyle, G., Baldwin, C. & Phillpot, M.Managing metabolic disturbances and lipodystrophy: diet, exercise, and smoking advice. Acquired Immune Deficiency Syndrome Read 11: 12 (2001), 589–92Google ScholarPubMed
Hadigan, C., Jeste, S., Anderson, E. J., Tsay, R., Cyr, H. & Grinspoon, S.Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin. Infect. Dis. 33: 5 (2001), 710–7CrossRefGoogle ScholarPubMed
Mauss, S., Wolf, E. & Jaeger, H.Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann. Intern. Med. 131: 4 (1999), 313–4CrossRefGoogle ScholarPubMed
Estrada, V., Villar, N. G., Larrad, M. T., Lopez, A. G., Fernandez, C. & Serrano-Rios, M.Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin. Infect. Dis. 35: 1 (2002), 69–76CrossRefGoogle ScholarPubMed
Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., Cruz, J. J. & Gonzalez-Lahoz, J.Risks and benefits of replacing protease inhibitors by nevirapine in Human Immunodeficiency Virus-infected subjects under long-term successful triple combination therapy. Acquired Immune Deficiency Syndrome 14: 7 (2000), 807–12Google Scholar
Martinez, E., Conget, I., Lozano, L., Casamitjana, R. & Gatell, J. M.Reversion of metabolic abnormalities after switching from Human Immunodeficiency Virus-1 protease inhibitors to nevirapine. Acquired Immune Deficiency Syndrome13: 7 (1999), 805–10Google Scholar
Valk, M., Kastelein, J. J., Murphy, R. L.. Nevirapine-containing antiretroviral therapy in Human Immunodeficiency Virus-1 infected patients results in an anti-atherogenic lipid profile. Acquired Immune Deficiency Syndrome 15: 18 (2001), 2407–14Google Scholar
Carr, A., Workman, C., Smith, D. E.. Abacavir substitution for nucleoside analogs in patients with Human Immunodeficiency Virus lipoatrophy: a randomized trial. J. Am. Med. Assoc. 288: 2 (2002), 207–15CrossRefGoogle ScholarPubMed
McComsey, G., Lonergan, T., Fisher, R., Sension, M., Hoppel, C. & Hessenthaler, S. Improvements in lipoatrophy are observed after 24 weeks when stavudine is replaced by either abacavir or zidovudine. In 9th Conference on Retroviruses and Opportunistic Infections, February 2002. Seattle, WA (2002)
Walli, R., Huster, K., Bogner, J. & Goebel, F. Switching from Pentamidine Isothionate to Abacavir improves insulin sensitivity and fasting lipids — 12-month follow-up. In 8th Conference on Retroviruses and Opportunistic Infections, February, 2001. Chicago, Interleukin (2001)
Currier, J. S. Metabolic complications of antiretroviral therapy and Human Immunodeficiency Virus infection. In Medscape Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Annual Update 2001. Medscape (2001)
Fisac, C., Fumero, E., Crespo, M. et al. A randomized trial of metabolic and body composition changes in patients switching from Pentamidine Isothionate-containing regimens to abacavir, efavirenz, or nevirapine. In 9th Conference on Retroviruses and Opportunistic Infections, February, 2002. Seattle, WA (2002)
John, M. & Mallal, S. A.Hyperlactatemia syndromes in people with Human Immunodeficiency Virus infection. Curr. Opin. Infect. Dis. 15 (2002), 23–9CrossRefGoogle Scholar
Haas, R. H.A comparison of genetic mitochondrial disease and nucleoside analogue toxicity. Does fetal nucleoside toxicity underlie reports of mitochondrial disease in infants born to women treated for Human Immunodeficiency Virus infection?Ann. N. Y. Acad. Sci. 918 (2000), 247–61CrossRefGoogle Scholar
Vu, T. H., Sciacco, M., Tanji, K.. Clinical manifestations of mitochondrial Deoxyribonucleic Acid depletion. Neurology 50: 6 (1998), 1783–90CrossRefGoogle Scholar
John, M., Moore, C. B., James, I. R.. Chronic hyperlactatemia in Human Immunodeficiency Virus-infected patients taking antiretroviral therapy. Acquired Immune Deficiency Syndrome 15: 6 (2001), 717–23Google Scholar
Boubaker, K., Flepp, M., Sudre, P.. Hyperlactatemia and antiretroviral therapy: the Swiss Human Immunodeficiency Virus Cohort Study. Clin. Infect. Dis. 33: 11 (2001), 1931–7CrossRefGoogle ScholarPubMed
Vrouenraets, S. M. E., Treskes, M., Regez, R. M. et al. Hyperlactatemia in Human Immunodeficiency Virus-infected patients: the role of NRTI treatment. In 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Interleukin (2001)
Brinkman, K.Management of hyperlactatemia: no need for routine lactate measurements. Acquired Immune Deficiency Syndrome 15: 6 (2001), 795–7Google ScholarPubMed
Giaquinto, C., Romeo, A., Giacomet, V.. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent Human Immunodeficiency Virus transmission. Acquired Immune Deficiency Syndrome 15: 8 (2001), 1074–5Google Scholar
Alimenti, A., Burdge, D. R., Oglivie, G. S., Money, D. M. & Forbes, J. C. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antirectroviral therapy. Pediatr. Infect. Dis. J. 22: 9 (2003), 782–9CrossRefGoogle Scholar
Gerard, Y., Maulin, L., Yazdanpanah, Y.. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. Acquired Immune Deficiency Syndrome 14: 17 (2000), 2723–30Google ScholarPubMed
Lonergan, J. T., Behling, C., Pfander, H., Hassanein, T. I. & Mathews, W. C.Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin. Infect. Dis. 31: 1 (2000), 162–6CrossRefGoogle ScholarPubMed
Scalfaro, P., Chesaux, J. J., Buchwalder, P. A., Biollaz, J. & Micheli, J. L.Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intens. Care Med. 24: 3 (1998), 247–50CrossRefGoogle ScholarPubMed
Miller, K. D., Cameron, M., Wood, L. V., Dalakas, M. C. & Kovacs, J. A.Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann. Intern. Med. 133: 3 (2000), 192–6CrossRefGoogle ScholarPubMed
Church, J. A., Mitchell, W. G., Gonzalez-Gomez, I.. Mitochondrial Deoxyribonucleic Acid depletion, near-fatal metabolic acidosis, and liver failure in an Human Immunodeficiency Virus-infected child treated with combination antiretroviral therapy. J. Pediatr. 138: 5 (2001), 748–51CrossRefGoogle Scholar
Scalfaro, P., Chesaux, J. J., Buchwalder, P. A., Biollaz, J. & Mitcheli, J. L.Severe transient neonated lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med. 24: 3 (1998), 247–50CrossRefGoogle Scholar
Blanche, S., Tardieu, M., Rustin, P.. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354: 9184 (1999), 1084–9CrossRefGoogle ScholarPubMed
Culnane, M., Fowler, M., Lee, S. S.. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to Human Immunodeficiency Virus-infected women. Pediatric Acquired Immune Deficiency Syndrome Clinical Trials Group Protocol 219/076 Teams. J. Am. Med. Assoc. 281: 2 (1999), 151–7CrossRefGoogle Scholar
Lindegren, M. L., Rhodes, P., Gordon, L. & Fleming, P.Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally Human Immunodeficiency Virus-exposed children in pediatric Human Immunodeficiency Virus surveillance. Ann. N. Y. Acad. Sci. 918 (2000), 222–35CrossRefGoogle Scholar
Bulterys, M., Nesheim, S., Abrams, E. J.. Lack of evidence of mitochondrial dysfunction in the offspring of Human Immunodeficiency Virus-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal Acquired Immune Deficiency Syndrome Collaborative Transmission Study. Ann. N. Y. Acad. Sci. 918 (2000), 212–21CrossRefGoogle Scholar
Dominguez, K., Bertolli, J., Fowler, M.. Lack of definitive severe mitochondrial signs and symptoms among deceased Human Immunodeficiency Virus-uninfected and Human Immunodeficiency Virus-indeterminate children less than or 5 years of age. Pediatric Spectrum of Human Immunodeficiency Virus Disease project (Pediatric Spectrum of Disease), USA. Ann. N. Y. Acad. Sci. 918 (2000), 236–46CrossRefGoogle ScholarPubMed
The Perinatal Safety Review Working Group. Nucleoside exposure in the children of Human Immunodeficiency Virus-infected women receiving antiretroviral drugs: abscence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J. Acquired Immune Deficiency Syndrome 25 (2000), 261–8CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×